helplinedonate
  • Announcements

    • ForumAdmin

      Frequently Asked Questions - Step by step guides

      Do you need assistance registering, logging in, posting, etc? Please visit the all new Frequently Asked Question Forum for step-by-step guides. Click the link below to access these helpful guides. Frequently Asked Questions
    • ForumAdmin

      Recursos Nuevos en Español

      http://www.parkinson.org/ayuda   http://www.parkinson.org/espanol    
    • ForumAdmin

      Línea de Ayuda 1-800-473-4636

      Línea de Ayuda 1-800-473-4636   ¿Qué es la línea de ayuda 1-800-4PD-INFO (473-4636) de la Fundación Nacional de Parkinson? Es un número de teléfono gratuito que ayuda a las personas con la enfermedad de Parkinson, sus familiares, amigos y profesionales de salud, a solucionar diferentes inquietudes.   La línea de ayuda ofrece: Información actualizada Apoyo emocional Referidos a profesionales de salud Recursos comunitarios Amplia variedad de publicaciones gratis    
Sign in to follow this  
Followers 0
Dr. Okun

Post of the Week: Surfing the PD Pipeline for New Therapies

3 posts in this topic

Dear forum members,

 

Dr. Robert Hauser has recently penned an outstanding paper reviewing all the new therapies in the Parkinson's disease pipeline. Dr. Hauser is professor at the NPF Center of Excellence at the University of South Florida in Tampa.

 

Here is the link to the article which is free access through pubmed: http://www.ncbi.nlm.nih.gov/pubmed/22035030

 

 

Int J Neurosci. 2011;121 Suppl 2:53-62.

Future Treatments for Parkinson's Disease: Surfing the PD Pipeline.

Hauser RA.

Source

Departments of Neurology, Molecular Pharmacology and Physiology, College of Medicine , University of South Florida, Tampa, Florida USA.

Abstract

ABSTRACT Our current wish list for the treatment of Parkinson's disease (PD) includes therapies that will provide robust and sustained antiparkinsonian benefit through the day, ameliorate or prevent dyskinesia, and slow or prevent the progression of the disease. In this article, I review selected new therapies in clinical development for motor features or treatment complications of PD, and some that may slow disease progression. These include adenosine 2a (A2a) antagonists (istradefylline, preladenant, and SYN115), levodopa/carbidopa intestinal gel (LCIG), IPX066-an extended-release formulation of carbidopa/levodopa, XP21279-a sustained-release levodopa prodrug, ND0611-a carbidopa subcutaneous patch, safinamide-a mixed mechanism of action medication that may provide both MAO-B and glutamate inhibition, PMY50028-an oral neurotrophic factor inducer, antidyskinesia medications (AFQ056 and fipamezole), and gene therapies (AAV2-neurturin and glutamic acid decarboxylase gene transfer). Some of these therapies will never be proven efficacious and will not come to market while others may play a key role in the future treatment of PD.

 

PMID: 22035030 [PubMed - in process]

LinkOut - more resources

 

Supplemental Content

 

Related citations

Review Treatment of Parkinson's disease : what's on the horizon?

[CNS Drugs. 2005] Treatment of Parkinson's disease : what's on the horizon?

Wu SS, Frucht SJ.

CNS Drugs. 2005; 19(9):723-43.

Review Adenosine A2A receptor antagonists for Parkinson's disease: rationale, therapeutic potential and clinical experience.

[Drugs Aging. 2005] Adenosine A2A receptor antagonists for Parkinson's disease: rationale, therapeutic potential and clinical experience.

Hauser RA, Schwarzschild MA.

Drugs Aging. 2005; 22(6):471-82.

Crossover comparison of IPX066 and a standard levodopa formulation in advanced Parkinson's disease.

[Mov Disord. 2011]Crossover comparison of IPX066 and a standard levodopa formulation in advanced Parkinson's disease.

Hauser RA, Ellenbogen AL, Metman LV, Hsu A, O'Connell MJ, Modi NB, Yao HM, Kell SH, Gupta SK.

Mov Disord. 2011 Oct; 26(12):2246-52. Epub 2011 Jul 13.

Review [Pharmacological treatments of Parkinson's disease].

[Nihon Yakurigaku Zasshi. 2001] [Pharmacological treatments of Parkinson's disease].

Nomoto M, Iwata S, Kaseda S.

Nihon Yakurigaku Zasshi. 2001 Feb; 117(2):111-22.

Review Does levodopa slow or hasten the rate of progression of Parkinson's disease?

[J Neurol. 2005] Does levodopa slow or hasten the rate of progression of Parkinson's disease?

Fahn S, and the Parkinson Study Group.

J Neurol. 2005 Oct; 252 Suppl 4:IV37-IV42.

See reviews...

See all...

Recent activity

Clear Turn Off

Future Treatments for Parkinson's Disease: Surfing the PD Pipeline.

Future Treatments for Parkinson's Disease: Surfing the PD Pipeline.

Int J Neurosci. 2011 ;121 Suppl 2:53-62.

PubMed

[Deep brain stimulation - expectations and doubts : A nationwide questionnaire ...

[Deep brain stimulation - expectations and doubts : A nationwide questionnaire study of patients with Parkinson's disease and their family members.]

Nervenarzt. 2011 Nov 13. [Epub ahead of print]

PubMed

okun ms (227)

PubMed

See more...

You are here: NCBI > Literature > PubMedWrite to the Help Desk

Simple NCBI Directory

GETTING STARTED

NCBI Education

NCBI Help Manual

NCBI Handbook

Training & Tutorials

RESOURCES

Chemicals & Bioassays

Data & Software

DNA & RNA

Domains & Structures

Genes & Expression

Genetics & Medicine

Genomes & Maps

Homology

Literature

Proteins

Sequence Analysis

Taxonomy

Training & Tutorials

Variation

POPULAR

PubMed

Nucleotide

BLAST

PubMed Central

Gene

Bookshelf

Protein

OMIM

Genome

SNP

Structure

FEATURED

GenBank

Reference Sequences

Map Viewer

Genome Projects

Human Genome

Mouse Genome

Influenza Virus

Primer-BLAST

Sequence Read Archive

NCBI INFORMATION

About NCBI

Research at NCBI

NCBI Newsletter

NCBI FTP Site

NCBI on Facebook

NCBI on Twitter

NCBI on YouTube

NLM NIH DHHS USA.gov

Share this post


Link to post
Share on other sites

Thank you for your link. Your site is very organized and interesting!

Share this post


Link to post
Share on other sites
Sign in to follow this  
Followers 0